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ABSTRACT  
Despite the great advances in fighting cancer, many therapies still have heavy side effects, 
thus urging the development of highly selective and safe treatments with a wide range of 
applicability. Sonodynamic therapy (SDT) is an innovative bimodal anticancer approach in 
which two, normally non-toxic components - one chemical, a sonosensitizer and one physical, 
ultrasound - selectively combine to cause oxidative damage and subsequent cancer cell death. 
In this study, we investigate the anticancer effect of SDT using shock waves (SWs) to activate 
protoporphyrin IX (PpIX) cytotoxicity on a Mat B-III syngeneic rat breast cancer model. 
The SDT-treated group saw a significant decrease (p < 0.001) in magnetic resonance imaging 
(MRI) tumor size measurements 72 h after treatment with PpIX precursor 5-aminolevulinic 
acid (ALA) and SWs. This occurred together with significant increase (p < 0.01) in apparent 
diffusion coefficients between pre- and post-treatment MR tumor maps and strong increase in 
necrotic and apoptotic histological features 72 h post-treatment. Moreover, significant HIF1A 
mRNA expression up-regulation was observed along with the prominent selective cleavage of 
poly (ADP-ribose) polymerase (PARP) and increased autophagy related protein LC3A/B 
expression in SDT-treated tumors, as compared to untreated tumors 72 h post-treatment. Then, 
the anticancer effect of SDT can be boosted by SWs making them a valid technology for 
furthering investigations into this innovative anticancer approach. 
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INTRODUCTION 
Progress in anticancer therapy can be achieved by placing emphasis on less thoroughly 
investigated bimodal anticancer approaches which, preferably consist of non-invasive 
treatments and which make use of synergistic effects between chemical compounds and 
external stimuli, such as heat, light or ultrasound (Urban et al., 2013; Ahmad et al. 1998; 
Hayashi et al., 2009). Due to its relatively low tissue attenuation coefficient, ultrasound has 
the ability to deeply penetrate biological tissues differently than light (Leighton, 2007). The 
absorption of ultrasound energy can lead to the heating of tissues and this has been used to 
therapeutic intent in high intensity focused ultrasound (HIFU) therapy (Kennedy, 2005). 
Recent efforts have discovered that benefits can also be acquired from non-thermal ultrasound 
effects, especially acoustic cavitation (Frenkel, 2008). Indeed non-thermal ultrasound can 
modulate cell membrane properties and activate specific chemical agents (Frenkel, 2008; 
Wood and Sehgal, 2015). Acoustic cavitation can be divided into two types, i.e. non-inertial 
(stable) and inertial (collapse or transient), which can only take place if acoustic pressure 
amplitude is higher than the pressure threshold for cavitation in the tissue under investigation. 
Inertial cavitation then produces vapor- or gas filled cavities (microbubbles) in the insonated 
milieu, that first increase in volume and then implode violently, producing ‘hot spots’ 
characterized by extremely high temperatures and pressure in a very small space. This 
phenomenon allows such harsh conditions to be reached without affecting bulk temperature 
and pressure and therefore promotes mechanisms, such as sonoluminescence and 
sonochemical reactions (Suslick and Flannigan, 2008). Inertial cavitation can therefore cause 
energy transfer which triggers electronic excitation, from the ground state into an excited state, 
in sonosensitive molecules (Tachibana et al., 2008). 
Sonodynamic therapy (SDT) typically refers to the selective uptake of a porphyrin-based 
sonosensitizer into cancer cells, followed by exposure to ultrasound which generates highly 
reactive cytotoxic products, such as reactive hydroxyl radicals, hydrogen atoms, alkoxyl and 
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peroxyl radicals and singlet molecular oxygen, which in turn cause damage to cancer cells 
(Tachibana et al., 2008). The peroxyl radicals are the key sonodynamic radical species as they 
possess longer lifetimes and the ability to diffuse longer distances (Wallace, 1997). 
Protoporphyrin IX (PpIX) is one of the most commonly used sonosensitizers and its 
accumulation in cancer cells can be produced via the administration of its precursor, 5-
aminolevulinic acid (ALA) (Chen et al., 2014). PpIX is produced during the heme cycle, 
while the negative feedback system, that prevents its accumulation, is modified in cancerous 
cells due to enzymatic defects (Collaud et al., 2004). Indeed, PpIX from ALA has been shown 
to accumulate preferably in cancerous cells over healthy cells and it is currently in widespread 
use in malignancy detection and treatment (Millon et al., 2010; Wachowska et al., 2011). 
Despite the effectiveness that SDT has demonstrated in experimental tumor models (Gao et 
al., 2013; Song et al., 2014; Tsuru et al., 2012; Costley et al, 2015), we only have a limited 
understanding of the mechanism of interaction between ultrasound and sonosensitizer in 
tumor tissues, even though inertial cavitation seems to play a crucial role. The most important 
parameters for inducing inertial cavitation are the ultrasound insonation technique used and 
peak ultrasound wave pressure (Leighton, 2007). Therapeutic ultrasound usually produces 
non-thermal effects that are difficult to isolate from the thermal ones. Therefore, our group 
has introduced the use of shock waves (SWs) to trigger sonosensitizer cytotoxicity, in order to 
minimize the thermal effect produced by ultrasound and enhance inertial cavitation. 
SWs are sharp discontinuities involving a sudden change in pressure and density which can 
induce in vivo bioeffects (Millán-Chiu et al., 2014). A typical pressure waveform at the focus 
in water consists of a compressive wave with a peak positive pressure in the range of 30–150 
MPa and a phase duration of 0.5–3 µs, followed by a tensile wave with a peak negative 
pressure that drops to 20 MPa and a duration of 2–20 µs, which is responsible for cavitation 
occuring. The low peak negative acoustic pressures of common therapeutic ultrasound are 
usually 0.2 MPa and produce stable cavitation (Lukes et al., 2015). 
  
6 
 
SWs have been used in extracorporeal shock wave lithotripsy for many years where it non-
invasively treats patients with stone diseases, while more novel applications, such as drug 
delivery and gene therapy, are currently emerging (Millán-Chiu et al., 2014; Rassweiler et al., 
2011; Steinhauser and Schmidt, 2014). The in vivo treatment of tumors by SWs alone has 
been shown to be ineffective in inhibiting tumor growth (Lukes et al., 2015), whereas some 
evidence has been obtained to suggest that combining SWs and sonosensitizer results in 
sonodynamic tumor growth inhibition (Canaparo et al., 2013; Canaparo et al., 2006; Serpe et 
al., 2011). Since strongest evidences are needed to confirm SDT as a real anticancer treatment 
option, in the present study, we investigate the SWs’ ability to induce in vivo PpIX 
cytotoxicity leading to tumor growth inhibition in a Mat B-III syngeneic rat breast cancer 
model.  
 
METHODS 
Sonodynamic treatment 
The rat mammary adenocarcinoma cell line, Mat B III, obtained from the American Type 
Culture Collection (ATCC, Rockville, MD, USA), was maintained in McCoy’s 5A modified 
medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin and 100 µg/mL 
streptomycin (Sigma Aldrich, St. Louis, MO, USA), at +37 °C in a humidified atmosphere 
containing 5% CO2. Cell pellets (1 × 106 cells), in 0.5 mL physiological saline, were 
orthotopically injected into the abdominal mammary fat pad of inbred 12 week-old female 
Fisher 344 rats (Charles River Laboratories, Milano, Italy) under isoflurane anesthesia. In 
three separate experiments, the animals were randomly assigned to treatment groups, with at 
least four animals per group. 
SDT was carried out when the subcutaneous tumors reached nearly 500 mm3 in volume, 
typically within nine days. Experimental groups were treated on day 9 with a single iv 
injection, into the tail vein, of either physiological saline (0.5 mL), ALA (375 mg/kg bw) or 
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SWs alone (0.88 mJ/mm2, 500 impulses, 4 impulses/sec) or a combination of ALA and SWs 
(375 mg/kg bw ALA 4 h before SW exposure at 0.88 mJ/mm2, 500 impulses, 4 impulses/sec). 
Aminolevulinic acid powder (Sigma Aldrich) was dissolved in physiological saline at a dose 
of 375 mg/kg bw immediately before each administration. All animals were sacrificed at the 
end of the study (day 12) and tumor tissue samples were maintained in 10% buffered formalin 
for histology and in Allprotect Tissue Reagent (Qiagen, Milano, Italy) for mRNA and protein 
analyses. 
SDT was carried out using an “energy-focused”	  piezoelectric device (Piezoson 100; Wolf, 
Knittlingen, Germany) and the energy at the focal point, i.e., energy flux density (EFD) per 
impulse, was recorded as mJ/mm2. Focal area is defined as the area in which 50% of the 
maximum energy is reached (10 mm lenght in the SW axis direction and 2.5 mm diameter 
perpendicular to this axis). Tumor bearing rats were anesthetized with 1-2% isoflurane in air 
and O2, fixed to a board in a supine position with the tumor facing upwards and ultrasound gel 
applied to the naked skin.  A secured, acoustically adapted gel pad allowed a 5 mm SW 
penetration depth to be achieved by the transducer. The experimental protocol was approved 
by the Ethics Committee of the University of Torino, Italy. 
Magnetic resonance imaging  
Animals were imaged using a dedicated whole body rat coil in a high field (7T) magnetic 
resonance imaging (MRI) scanner (Bruker, PharmScan, Germany). Rats were anesthetized 
with isoflurane that had been vaporized with O2. Isoflurane was used at 3.0% for induction 
and at 1.0% -2.0% for maintenance. Spin echo (RARE) imaging (TR/TE/NEX = 3000/8.5/2, 
slice thickness 1.5 mm, FOV 50 mm, matrix 256 x 256; 15 slices, imaging time = 2.5 min) 
was used to calculate tumor volume and analyze tumor morphology. Typically, 15–20 coronal 
slices were acquired to cover the whole tumor. Each rat was scanned on day 8 (24 h pre-
treatment) and 12 (72 h post-treatment) in order to characterize SDT tumor response. 
Diffusion-weighted images were acquired at a repetition time of 3100 ms and an echo time of 
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32 ms. Seven images were obtained with different gradient scalings, resulting in b-­‐values of 0, 
100, 300, 400, 600, 800, 1000 smm-­‐2. Signal intensities measured from the images that had 
been acquired at different b-­‐values S(b) and were numerically fitted against the model, S(b) = 
S(b=0) e-­‐bADCz, on a pixelwise basis. The resulting longitudinal component of the apparent 
diffusion coefficient (ADC) values were then displayed and analyzed as a parametric map. 
The tumor ADC values at the two time points (24 h pre-­‐ and 72 h post-treatment) were then 
analyzed. 
Histopathological analysis  
Tumor samples were fixed in 10% formalin 72 h post-treatment, blocked in a paraffin resin, 
cut to 4 µm, deparaffinized in xylene and rehydrated with alcohol. Sections were then stained 
with hematoxylin-eosin for histological examination by light microscopy (Leica DM600, 
Wetzlar, Germany).  
Real Time RT-PCR 
Tumor samples were collected in Allprotect Tissue Reagent (Qiagen) 72 h post-treatment and 
stored at -80 °C. Total RNA was obtained using the AllPrep® DNA/RNA/protein Kit (Qiagen) 
and concentration (µg/mL) was determined using the Quant-iT™ RNA Assay Kit (Invitrogen, 
Milano, Italy) on a fluorometer Qubit (Invitrogen). RNA sample integrity was determined 
using the total RNA 6000 Nano Kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, 
Milano, Italy). 500 ng of total RNA was reverse transcribed in a 20 µL cDNA reaction 
volume using the QuantiTect® Reverse Transcription Kit, while real time PCR analysis was 
carried out using SsoFast™ EvaGreen on the MiniOpticon™ Real Time PCR system (Bio-
Rad, Milano, Italy). A QuantiTect Primer Assay was used as the gene-specific primer pair for 
APAF-1 (QT01611225), BAD (QT00190407), BCL2 (QT00184863), HIF1A (QT00182532), 
MMP9 (QT00178290), NFE2L2 (QT00183617), NQO1 (QT00186802), RNR1 (QT00199374), 
and TP53 (QT00193522). The transcript of the reference gene ribosomal 18s and 28s RNA 
(RNR1) was used to normalize mRNA data. The PCR protocol conditions used have 
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previously been reported (Canaparo et al., 2013) and data analysis quantification was 
performed using Bio-Rad CFX Manager Software version 1.6 (Bio-Rad). 
Western Blot analysis 
Tumor samples were collected in Allprotect Tissue Reagent (Qiagen) 72 h post-treatment and 
stored at - 80 °C. Total protein was obtained using the AllPrep® DNA/ RNA/ protein Kit 
(Qiagen) and concentration (µg/mL) was determined using the Quant-iT™ Protein Assay Kit 
on the fluorometer Qubit (Invitrogen). Equal amounts of protein (30 µg) were heat 
denaturated in sample-loading buffer (50 mmol/L Tris-HCl, pH 6.8, 100 mmol/L 
dithiothreitol, 2% SDS, 0.10% bromophenol blue, 10% glycerol), resolved by SDS-PAGE 
(Any kD™ Mini-PROTEAN® TGX™ Gel, Bio-Rad) and transferred to nitrocellulose 
membranes using Trans-Blot® Turbo™ Transfer System (Bio-Rad). Membranes were stained 
with Ponceau Red (Sigma Aldrich) after the transfer procedure to check for the complete 
protein transfer and equal lane-to-lane protein loading. Filters were then blocked with Tris-
buffered saline containing 0.05% Tween (Sigma Aldrich) and 5% non-fat dry milk and 
incubated overnight with the following primary antibodies (Abcam Company, Burlingame, 
California): beta actin (β-actin, Abcam 8226), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH, Abcam 9484), LC3A/B (Abcam 128025), poly-ADP-ribose polymerase (PARP, 
Abcam 32138) and Ras homolog gene family member A (RhoA, Abcam 86297). Peroxidase-
conjugated IgG (Abcam) was used as secondary antibodies. The membrane-bound immune 
complexes were detected using an enhance chemioluminescence system (ECL, GE Healthcare, 
Milano, Italy). Quantification of the bands was performed by densitometric analysis using 
TotalLab Software, version 2006 (Nonlinear Dynamics, Newcastle on Tyne, UK). 
Statistical analysis 
Results are expressed as the average value ± standard deviation (SD) throughout. Statistical 
analyses were performed on Graph-Pad Prism 5.0 software (La Jolla, CA, USA). The two-
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tailed Mann-Whitney U test and the Kruskall-Wallis test were used to calculate the threshold 
of significance. Statistical significance was set at p < 0.05. 
 
RESULTS 
Sonodynamic treatment effect on tumor growth 
MRI tumor size measurements clearly show that the groups demonstrated no significant 
difference in tumor size before treatment, while the SDT-treated group saw a tumor volume 
decrease, of about 60% (0.79 ± 0.39 cm3), 72 h after the treatment.  
This is considerable when compared to the untreated group (2.08 ± 0.20 cm3), the ALA- (1.56 
± 0.74 cm3) and SW- (1.64 ± 0.28 cm3) treated groups (Figure 1A). SWs then induced in vivo 
PpIX cytotoxicity causing cancer cell death which was confirmed by histological analyses. 
Indeed, histological sections of control tumors, i.e. untreated (Figure 1B), ALA- (Figure 1C) 
or SW-treated (Figure 1D) tumors, showed that the integrated tumor cells were densely 
distributed, whereas tumor sections of SDT-treated group highlighted a strong increase in 
pyknosis, cell debris, cell shrinkage, increased intercellular space and necrotic subregions 
(Figure 1E). Moreover, no evidence of blood vessel injury and/or blood cell extravasation was 
found in the tumor sections of SW-treated groups, whether they had received ALA or not, as 
special attention was paid to detecting morphological alteration that may have been caused by 
SW mechanical effects. 
MRI can provide in vivo information about tissue physiology and morphology, whereby it 
furnishes a non-invasive assessment of the tumor response by monitoring treatment-induced 
changes in tissue properties. Indeed, water molecule diffusion indirectly characterizes the 
tissue microenvironment as it is associated with cellular integrity and pathological conditions 
(Charles-Edwards and deSouza, 2006). Diffusion weighted (DW)-MRI detects water 
molecule displacement and its potential for monitoring a tumor's response to PDT has been 
demonstrated in several studies. Wang et al. (2010) have stated that morphologic changes, 
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such as broken cells, lead to changes in water diffusion within the tumor and therefore 
provides the mechanism by which DW-MRI detects early tumor response. We therefore 
monitored the tumor response to SDT using DW-MR images 24 h pre- and 72 h post-
treatment. DW-MRI and ADC values were analyzed for all treatment groups: sonosensitizer 
alone, SWs alone and the combination of sonosensitizer and SWs. 
Figure 2 shows representative ADC maps, at days 8 and 12 after tumor cell inoculation, of an 
untreated rat (Figure 2A, B) and a SDT-treated rat (Figure 2C, D) together with the 
corresponding T2-weighted images (Figure 2E, F and G, H). An increase in ADC, within the 
tumor and surrounding edema, is clearly visible by the bright region in the ADC map of the 
SDT-treated rat at day 12, 72 h post-SDT (Figure 2D) compared with the ADC map at day 8, 
24 h pre-SDT (Figure 2C). No significant differences were observed in ADC maps of 
untreated rat between day 8 and 12 (Figure 2A, B). The average ADC value of the SDT-
treated tumors increased at day 12, 72 h after SDT (p < 0.01) compared to the average ADC 
value of the SDT-treated tumors at day 8, 24 h pre-SDT (Figure 2I). The average 24 h pre-
SDT ADC value was 1.02 ± 0.15 × 10-3 mm2/s and the average 72 h post-SDT ADC value  
was 1.37 ± 0.06 × 10-3 mm2/s. Increased ADC values in the SDT- treated tumors might then 
indicate higher water diffusivity in 72 h post-SDT tumors compared with 24-h pre-SDT 
tumors. In the untreated rat no significant differences were observed between ADC maps at 
day 8 and 12 (Figure 2A, B, H). No significant differences in the average ADC value of 
untreated, sonosensitizer alone or SW alone-treated groups were observed (Figure 2I). 
Sonodynamic treatment effect  on gene and protein expression  
As PpIX sonosensitation can induce cell death via oxidative damage and apoptosis, we 
analyzed a panel of genes involved in these pathways according to our previous in vitro work 
(Canaparo et al., 2013). mRNA gene expression was evaluated in samples from all 
experimental groups 72 h after treatment. Figure 3 shows increased mRNA expression of 
oxidative stress related genes, such as the transcription factor Hypoxia Inducible Factor 1 
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Alpha Subunit (HIF1A) (p < 0.05), in the SDT-treated tumors as compared to the untreated 
tumors. Moreover, an increase in the Apoptotic Peptidase Activating Factor 1 (APAF1) 
mRNA expression, although it was not statistically significant, and a decrease in extracellular 
matrix endopeptidases Matrix Metallopeptidase 9 (MMP9) mRNA expression were observed, 
whereas no significant differences in mRNA gene expression was observed for the apoptosis 
related genes, APAF1, BAD and BCL-2, or the oxidative stress related genes, NQO1 and 
NFE2L2. No statistically significant differences in the mRNA expression of the panel of 
genes was observed in ALA alone or SWs alone-treated tumors as compared to untreated 
tumors (data not shown).  
Since the selective cleavage of poly (ADP-ribose) polymerase (PARP) by several caspases, 
especially caspase-3, is a prominent apoptosis event, we performed a western blot analysis to 
investigate whether caspase-3 cleaves 113 kDa PARP to generate 85 and 29 kDa polypeptides 
in the SDT-treated group as compared to other experimental groups. The results in Figure 4A 
show representative images of significant cleavage in the SDT-treated group as compared to 
untreated, ALA alone or SWs alone-treated groups, at 72 h post-treatment. The PARP 
analysis results prompted us to focus our attention on SDT-treated tumors and investigate the 
protein expression of other cell death effectors. An increased expression of LC3A/B protein 
expression was observed in tumor tissues 72 h after SDT (Figure 4B), this protein is an 
indicator of autophagy, the basic catabolic mechanism for the degradation of unnecessary or 
dysfunctional cellular components via the action of lysosomes. A slight increase in RhoA 
protein expression, a small GTPase protein known to regulate actin cytoskeleton in the 
formation of stress fibers, was also detected in the SDT-treated tumors with respect to 
untreated tumors (Figure 4B). 
 
DISCUSSION 
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Umemura et al. (1990) and Tachibana et al. (1993) were the first to introduce the 
sonodynamic treatment in the 1990s using SDT as a new bimodal anticancer approach to 
trigger sensitizer cytotoxicity and overcome the main drawback of PDT, i.e., light’s relatively 
limited capacity to penetrate human tissues. Reactive oxygen species (ROS) and the resulting 
oxidative stress both play a pivotal role in sonodynamic induced cancer cell death (Misík and 
Riesz, 2000). The subcellular localization pattern of the sonosensitizer is extremely important 
for sonodynamic treatment efficiency due to the very short lifetimes and very short diffusion 
distances of some of the radical products derived from the sonosensitization produced during 
SDT. Thus, the SDT effect is determined by parameters that include both the sonosensitizer 
and ultrasound delivery patterns.  
The sonosensitizer PpIX accumulated mainly in the mitochondria of cancer cells, where it is 
produced from ALA. Interestingly, it was found that the relative change in PpIX fluorescence 
intensity may be able to discriminate breast cancer from normal mammary epithelial cells 
(Millon et al., 2010). Several studies have indicated that apoptosis may be responsible for 
SDT induced cancer cell death and that mitochondrial dysfunction may play a central role.  
As in vivo pressure measurements of SWs have shown that in vivo waveforms are roughly 
30% lower in peak amplitude than those measured in water, we carried out in vivo treatments 
using higher energy levels than those used in previous in vitro works (Canaparo et al., 2013; 
Canaparo et al., 2006).  
Our results show that tumor growth was significantly reduced by ALA and SWs-based SDT 
(Figure 1A) and provide a glimpse of possible future developments in the use of SWs, which 
is very much an emerging research area with numerous exciting prospects. Moreover, DW-
MRI was used to monitor SDT tumor response, as this technique might be able to predict 
treatment efficacy at an early time. Indeed, MRI provides the non-invasive in vivo monitoring 
of tumor tissue and may allow an assessment of tumor response to be carried out by 
monitoring changes in treatment-induced tissue properties. An increase in water molecule 
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mobility in necrotic tumors over the restricted diffusion in viable tumors may result in an 
increase in MRI ADC values (Charles-Edwards and deSouza, 2006). Wang et al. (2010) have 
reported that changes in ADC values may provide a useful tool with which to monitor early 
tumor response and determine the effectiveness of anticancer treatments, such as PDT. 
Induced tumor necrosis is characterized by massive cell damage, reduced cell density and 
increased intercellular space and thus also by the liberation of water molecules from cellular 
membrane restriction. Our results show that significant differences in ADC values 72 h after 
SDT (Figure 2I) are consistent with the tumor necrosis and nonvascular cell injury observed 
in the respective histological sections (Figure 1E). Moreover, no differences in histological 
sections and ADC values were found between untreated tumor tissues and those that had only 
been treated with ALA alone or SWs alone. Lukes et al. (2015) reported that mechanical 
stress induces cell tumor damage only with high overpressure SWs with positive pressure 
peak amplitudes of 372 MPa, which are significantly higher than those used in this work (90 
MPa). 
By analyzing the mechanism of action that underlines SDT, Tabuchi et al. (2008) have proven 
in vitro that there is a significant down-regulation of the genetic network associated with 
cellular proliferation, gene expression and cellular development and a significant up-
regulation of the genetic network associated with cellular movement, cell morphology and 
cell death after SDT. Our in vivo data also indicate that SDT affects gene and protein 
expression and provide novel insight into its bio-molecular mechanisms. Interestingly, the 
oxidative stress-related gene, HIF1A, was significantly up-regulated and the cellular 
movement related gene, MMP9, was significantly down-regulated, 72 h after SDT (Figure 3). 
Moreover, we observed the in vivo cleavage of PARP, a cellular substrate for caspase 3 and 7, 
indicating that apoptosis was induced in the SDT-treated tumors (Figure 4A). Since 
autophagy appears to promote or inhibit apoptosis according to specific stimuli and differing 
cell type (Cui et al., 2007; Pan et al., 2013) it was decided that the LC3A/B expression profile 
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should be investigated and, in fact, an increased level of expression was found in the SDT-
treated tumors (Figure 4B). Referring to autophagy and apoptosis in SDT, Su et al. (2015) 
demonstrated that apoptosis and autophagy occured with dependency on ROS production, 
whereas Wang et al. (2013) revealed that autophagy inhibition enhanced SDT-induced 
apoptosis in murine leukemia L1210 cells. Finally, a slight increase in RhoA expression 
(Figure 4B) was also observed. Our attention was focused on RhoA as it has been reported 
that PpIX from ALA may sensitize inside-out signaling proteins, such as Rho, that influence 
integrin binding to the substratum ligands and control the formation of stress fibers and 
general cellular response. Interestingly, the constitutive activation of RhoA has been 
demonstrated to negatively regulate cell migration due to the formation of excess stress fibers 
(Uzdensky et al., 2004)  
 
CONCLUSION 
In this work, we have shown as SWs can be considered a promising technology for in vivo 
sonodynamic applications since they can be focused by extracorporeal device to reach 
different depths in the body and activate sonosensitizer leading to cancer cell death. Indeed, 
the strength of this therapeutic approach relies on the possibility to selectively activate the 
drug in situ with a consequent improvement in drug specificity and efficacy. 
We would also like to stress that significant progress in this field can only be achieved 
through multidisciplinary research demonstrating the validity of this approach at preclinical 
level either for primary or metastatic cancer sites. Moreover, it is worth noting that the 
methodology has a great clinical translatability either in terms of the necessary devices for the 
focused shock waves application or in terms of the required bioactive anticancer agents (e.g. 
porphyrin derivatives) each one already approved for clinical use.  
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FIGURE LEGENDS 
Figure 1. Effect of SDT on Mat B III/ Fisher 344 tumor growth. Rats with growing tumors 
were treated with ALA and SWs (375 mg/Kg bw iv and 0.88 mJ/cm2 for 500 impulses, 4 
impulses/sec, respectively) 9 days after tumor cell inoculation and tumor volumes were 
determined by MRI on days 8 (24 h pre-treatment) and 12 (72 h post-treatment). A: the tumor 
volumes of each experimental group (n = 12) are reported as mean ± SD. Representative 
haematoxylin-eosin section images of an untreated tumor (B), a ALA-treated tumor (C), a 
SW-treated tumor (D), a ALA and SWs (SDT)-treated tumor (E), 72 h after treatment (10x 
magnification). Statistical significance versus untreated rats, *** p < 0.001. 
Figure 2. Diffusion weighted (DW)-MR images and ADC values at day 8 (24 h pre-
treatment) and day 12 (72 h post-treatment) after tumor cell inoculation. Representative ADC 
maps and corresponding T2-weighted images of an untreated tumor at day 8 (A, E) and 12 (B, 
F) and of a SDT-treated tumor at days 8, 24 h pre-treatment, (C, G) and 12, 72 h post-
treatment (D, H). An ADC increase, within the tumor and surrounding edema, is visible in the 
SDT-treated tumor (D) but not in the untreated tumor (B). ADC values for each experimental 
group (n = 12) are reported as mean ± SD. (I). Statistical significance versus pre-treatment 
ADC values, ** p < 0.01. 
Figure 3. SDT effect on mRNA expression 72 h post-SDT. RNR1 (ribosomal RNA 18S and 
28S) was used as a reference gene to normalize the data. The combined treatment between 
ALA and SWs (375 mg/Kg bw iv and 0.88 mJ/cm2 for 500 impulses, 4 impulses/sec) induced 
alterations in mRNA levels that are compared with those of the control, i.e. untreated rats, 
stated as 1 and shown by the dotted line. Data are reported as mean ± SD for three separate 
experiments, each experiment with at least four animals per group (n=12). Statistical 
significance versus untreated tumor: * p < 0.05. 
Figure 4. SDT effect on protein expression 72 h post-treatment. For each experimental group, 
two different representative samples are showed. A: sonodynamic treatment with ALA and 
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SWs (375 mg/Kg bw iv and 0.88 mJ/cm2 for 500 impulses, 4 impulses/sec) induced 
significant cleavage of poly (ADP-ribose) polymerase (PARP) 113 kDa nuclear protein, into 
two fragments of 29 kDa (C-terminal catalytic domain) and 85 kDa (N-terminal DNA-binding 
domain) in the SDT-treated tumors, as compared to untreated tumors, SWs alone or ALA 
alone-treated tumors. B: detection of the 22 kDa RhoA protein and of the 15 kDa LC3A/B 
protein. GAPDH was used as loading control. 
 
 
 
 
